{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:12:09Z","timestamp":1765609929150,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T00:00:00Z","timestamp":1548374400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001106","name":"New South Wales Workers' Compensation Dust Disease Board","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/501100001106","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00520-019-4648-0","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T16:04:02Z","timestamp":1548432242000},"page":"3509-3519","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Managing malignant pleural mesothelioma: experience and perceptions of health care professionals caring for people with mesothelioma"],"prefix":"10.1007","volume":"27","author":[{"given":"Anne","family":"Warby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haryana M.","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5739-5790","authenticated-orcid":false,"given":"Janette L.","family":"Vardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"issue":"14","key":"4648_CR1","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636\u20132644. \n                              https:\/\/doi.org\/10.1200\/JCO.2003.11.136","journal-title":"J Clin Oncol"},{"issue":"28","key":"4648_CR2","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"JP Meerbeeck van","year":"2005","unstructured":"van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, Legrand C, Bottomley A, Debruyne C, Giaccone G, European Organisation for Research, Treatment of Cancer Lung Cancer Group, National Cancer Institute of Canada (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23(28):6881\u20136889. \n                              https:\/\/doi.org\/10.1200\/JCO.20005.14.589","journal-title":"J Clin Oncol"},{"issue":"6","key":"4648_CR3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/01243894-200607000-00017","volume":"1","author":"P Ellis","year":"2006","unstructured":"Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS, Lung Cancer Disease Site Group of Cancer Care Ontario\u2019s Program in Evidence-based C (2006) The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 1(6):591\u2013601","journal-title":"J Thorac Oncol"},{"issue":"15","key":"4648_CR4","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1200\/JCO.2004.09.147","volume":"22","author":"AK Nowak","year":"2004","unstructured":"Nowak AK, Stockler MR, Byrne MJ (2004) Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module. J Clin Oncol 22(15):3172\u20133180. \n                              https:\/\/doi.org\/10.1200\/JCO.2004.09.147","journal-title":"J Clin Oncol"},{"issue":"14_suppl","key":"4648_CR5","doi-asserted-by":"publisher","first-page":"Abstract 8125","DOI":"10.1200\/jco.2004.22.14_suppl.8125","volume":"22","author":"PJ Hollen","year":"2004","unstructured":"Hollen PJ, Gralla RJ, Symanowski J, Liepa AM, Bizette GA (2004) Determining the frequency of quality of life (QL) assessment in chemotherapy treatment: using the LCSS-Meso in the randomized pemetrexed + cisplatin (C) trial in 448 patients with mesothelioma (MPM) as an example. J Clin Oncol 22(14_suppl):Abstract 8125. \n                              https:\/\/doi.org\/10.1200\/jco.2004.22.14_suppl.8125","journal-title":"J Clin Oncol"},{"issue":"1","key":"4648_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/ajco.12306","volume":"11","author":"SC Kao","year":"2015","unstructured":"Kao SC, van Zandwijk N, Clarke S, Vardy J, Lumba S, Tognela A, Ng W (2015) Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care. Asia Pac J Clin Oncol 11(1):85\u201392. \n                              https:\/\/doi.org\/10.1111\/ajco.12306","journal-title":"Asia Pac J Clin Oncol"},{"key":"4648_CR7","unstructured":"Physicians RCo (2018) National Mesothelioma Audit report 2018 (for the audit period 2014 - 2016). Royal College of Physicians, London"},{"issue":"2","key":"4648_CR8","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.lungcan.2015.05.014","volume":"89","author":"RA Damhuis","year":"2015","unstructured":"Damhuis RA, Khakwani A, De Schutter H, Rich AL, Burgers JA, van Meerbeeck JP (2015) Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England. Lung Cancer 89(2):212\u2013217. \n                              https:\/\/doi.org\/10.1016\/j.lungcan.2015.05.014","journal-title":"Lung Cancer"},{"issue":"4","key":"4648_CR9","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/j.1445-5994.2012.02925.x","volume":"43","author":"SC Kao","year":"2013","unstructured":"Kao SC, Clarke S, Vardy J, Corte P, Clarke C, van Zandwijk N (2013) Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia. Intern Med J 43(4):402\u2013410. \n                              https:\/\/doi.org\/10.1111\/j.1445-5994.2012.02925.x","journal-title":"Intern Med J"},{"key":"4648_CR10","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/CLEP.S105396","volume":"8","author":"JL Beebe-Dimmer","year":"2016","unstructured":"Beebe-Dimmer JL, Fryzek JP, Yee CL, Dalvi TB, Garabrant DH, Schwartz AG, Gadgeel S (2016) Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol 8:743\u2013750. \n                              https:\/\/doi.org\/10.2147\/CLEP.S105396","journal-title":"Clin Epidemiol"},{"key":"4648_CR11","unstructured":"Dhillon H, Warby A, Kao SC, Vardy J Chemotherapy for malignant mesothelioma: patient, caregiver and health professionals\u2019 perceptions of treatment and what influences access. In: IALSC World Conference on Lung Cancer, Sydney, Australia, 2013. J Thorac Oncol, p S1240"},{"issue":"2","key":"4648_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377\u2013381. \n                              https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010","journal-title":"J Biomed Inform"},{"key":"4648_CR13","unstructured":"Australian Bureau of Statistics (ABS): Australian Statistical Geography Standard (ASGS) (2011). Statistics ABo. edn., Canberra: Australian Capital Territory"},{"issue":"6","key":"4648_CR14","doi-asserted-by":"publisher","first-page":"E254","DOI":"10.3978\/j.issn.2072-1439.2013.11.28","volume":"5","author":"N Zandwijk van","year":"2013","unstructured":"van Zandwijk N, Clarke C, Henderson D, Musk AW, Fong K, Nowak A, Loneragan R, McCaughan B, Boyer M, Feigen M, Currow D, Schofield P, Nick Pavlakis BI, McLean J, Marshall H, Leong S, Keena V, Penman A (2013) Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. J Thorac Dis 5(6):E254\u2013E307. \n                              https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2013.11.28","journal-title":"J Thorac Dis"},{"issue":"13","key":"4648_CR15","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","volume":"36","author":"HL Kindler","year":"2018","unstructured":"Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, Jones CM, Miettinen M, Pass H, Rimner A, Rusch V, Sterman D, Thomas A, Hassan R (2018) Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36(13):1343\u20131373. \n                              https:\/\/doi.org\/10.1200\/JCO.2017.76.6394","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"4648_CR16","first-page":"s101","volume":"15","author":"MJ Verhoef","year":"2008","unstructured":"Verhoef MJ, Rose MS, White M, Balneaves LG (2008) Declining conventional cancer treatment and using complementary and alternative medicine: a problem or a challenge? Curr Oncol 15(Suppl 2):s101\u2013s106","journal-title":"Curr Oncol"},{"issue":"3","key":"4648_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/jme.2004.008755","volume":"31","author":"T Kleffens van","year":"2005","unstructured":"van Kleffens T, van Leeuwen E (2005) Physicians\u2019 evaluations of patients\u2019 decisions to refuse oncological treatment. J Med Ethics 31(3):131\u2013136. \n                              https:\/\/doi.org\/10.1136\/jme.2004.008755","journal-title":"J Med Ethics"},{"issue":"2","key":"4648_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.lungcan.2010.05.001","volume":"69","author":"P Blinman","year":"2010","unstructured":"Blinman P, Alam M, Duric V, McLachlan SA, Stockler MR (2010) Patients\u2019 preferences for chemotherapy in non-small-cell lung cancer: a systematic review. Lung Cancer 69(2):141\u2013147. \n                              https:\/\/doi.org\/10.1016\/j.lungcan.2010.05.001","journal-title":"Lung Cancer"},{"issue":"2","key":"4648_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/annonc\/mdj073","volume":"17","author":"ME O\u2019Brien","year":"2006","unstructured":"O\u2019Brien ME, Watkins D, Ryan C, Priest K, Corbishley C, Norton A, Ashley S, Rowell N, Sayer R (2006) A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 17(2):270\u2013275. \n                              https:\/\/doi.org\/10.1093\/annonc\/mdj073","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"4648_CR20","doi-asserted-by":"publisher","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","volume":"26","author":"P Baas","year":"2015","unstructured":"Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S, Committee EG (2015) Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v31\u2013v39. \n                              https:\/\/doi.org\/10.1093\/annonc\/mdv199","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"4648_CR21","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","volume":"73","author":"I Woolhouse","year":"2018","unstructured":"Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, Faivre-Finn C, Fennell DA, Holmes S, Kerr KM, Nakas A, Peel T, Rahman NM, Slade M, Steele J, Tsim S, Maskell NA (2018) British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax 73(Suppl 1):i1\u2013i30. \n                              https:\/\/doi.org\/10.1136\/thoraxjnl-2017-211321","journal-title":"Thorax"},{"issue":"22","key":"4648_CR22","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.1002\/cncr.26149","volume":"117","author":"MM Boxer","year":"2011","unstructured":"Boxer MM, Vinod SK, Shafiq J, Duggan KJ (2011) Do multidisciplinary team meetings make a difference in the management of lung cancer? Cancer 117(22):5112\u20135120. \n                              https:\/\/doi.org\/10.1002\/cncr.26149","journal-title":"Cancer"},{"issue":"9","key":"4648_CR23","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/sj.bjc.6602825","volume":"93","author":"LM Forrest","year":"2005","unstructured":"Forrest LM, McMillan DC, McArdle CS, Dunlop DJ (2005) An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 93(9):977\u2013978. \n                              https:\/\/doi.org\/10.1038\/sj.bjc.6602825","journal-title":"Br J Cancer"},{"key":"4648_CR24","volume-title":"The NHS cancer plan","author":"Health UDo","year":"2000","unstructured":"Health UDo (2000) The NHS cancer plan. Department of Health, London"},{"issue":"9","key":"4648_CR25","doi-asserted-by":"publisher","first-page":"e012092","DOI":"10.1136\/bmjopen-2016-012092","volume":"6","author":"AC Bibby","year":"2016","unstructured":"Bibby AC, Williams K, Smith S, Bhatt N, Maskell NA (2016) What is the role of a specialist regional mesothelioma multidisciplinary team meeting? A service evaluation of one tertiary referral centre in the UK. BMJ Open 6(9):e012092. \n                              https:\/\/doi.org\/10.1136\/bmjopen-2016-012092","journal-title":"BMJ Open"},{"key":"4648_CR26","unstructured":"Cancer Australia: \n                              https:\/\/canceraustralia.gov.au\/clinical-best-practice\/multidisciplinary-care\/all-about-multidisciplinary-care\/planning-multidisciplinary-care-meeting\n                              \n                           , All about multidisciplinary care. Australian Government, Accessed 11 July 2018"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-4648-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-4648-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-4648-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T19:19:33Z","timestamp":1579893573000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-4648-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["4648"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-4648-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2019,1,25]]},"assertion":[{"value":"3 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Drs Vardy, Dhillon, and Kao report grants from icare Dust Diseases Care for the conduct of the study which is the basis of the submitted work. Dr. Kao reports personal fees to his institution from MSD, Roche, AstraZeneca, Pfizer, and BMS, outside the submitted work. Dr. Dhillon reports honoraria paid to her institution from MSD outside the submitted work. The authors have full control of all primary data and agree to allow the journal to review the data if requested.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}